Supplementary Figure 9 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

• Maximum variant allele frequencies (VAF) show significant differences based on treatment response categories and tumor characteristics.
• Patients with evaluable disease exhibit varying VAF for detected somatic alterations across treatment subprotocols.
• Examination of baseline maximum VAF indicates genetic variability related to patient responses in a clinical trial.
• Stratification by treatment subprotocol reveals nuanced insights into tumor responses based on genetic information.

Abstract